As combined treatments of anti-CTLA-4 and anti-PD-1 antibodies have been demonstrated to be more effective in activating T cells within the tumors than single antibody treatment in mouse melanoma model31, as proof-of-concept we examined the effect of combined immune checkpoint inhibitors (anti-CTLA-4 and anti-PD-1) with POM-1. Here, CTLA4 is linked to melanoma.